ArticleCurrent oncology (Toronto, Ont.)2023

Ibrutinib Plus RCHOP versus RCHOP Only in Young Patients with Activated B-Cell-like Diffuse Large B-Cell Lymphoma (ABC-DLBCL): A Cost-Effectiveness Analysis.

Hayeong Rho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.